PAT after MI is Rs. 41 crore which is 162% increase
The revenue from operations in Q3 FY25 is Rs. 8,358.6 crore, up 16% YoY
Successfully transformed the organization from a two-country operation focused on development and manufacturing to a fully integrated company with a strong commercial engine bringing us closer to patients in over 120 countries
Difluprednate Ophthalmic Emulsion, 0.05% is a topical corticosteroid that is indicated in the treatment of inflammation and pain associated with ocular surgery
The first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma
The product will be marketed by Dr. Reddy's
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
Potential to optimize and build on the synergies in commercial operations, distribution, manufacturing, supply chain etc.
The proceeds from its fresh issuance to the extent of Rs 107 crore will be utilized for funding the capital expenditure requirements
Subscribe To Our Newsletter & Stay Updated